Phase IIIb study for relapsed/refractory pediatric/young adult acute lymphoblastic leukemia patients to be treated with CTL019.
Phase of Trial: Phase III
Latest Information Update: 13 Dec 2018
At a glance
- Drugs Tisagenlecleucel (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Expanded access
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 08 Dec 2018 Planned number of patients changed from 55 to 70.
- 10 Mar 2017 New trial record